Celgene News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

13.01.14	Celgene Lifts FY13 Outlook - Update (RTTNews)
13.01.14	Celgene Issues Q4 Earnings Outlook; Lifts FY13 Adj. EPS Outlook - Quick Facts (RTTNews)
08.01.14	ABRAXANE® plus Gemcitabin erhält europäische Marktzulassung zur Erstlinienbehandlung von Patienten mit metastasierendem Bauchspeicheldrüsenkrebs (Businesswire)
08.01.14	CGEN Plans Busy Year, CytoDyn Gets Going, OREX Gets FDA Date, DRRX On A High (RTTNews)
07.01.14	Celgene: EC OKs Abraxane Plus Gemcitabine For Metastatic Pancreatic Cancer (RTTNews)
07.01.14	ABRAXANE® Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer (Businesswire)
18.12.13	Acceleron To Receive $7 Mln Milestone Payment From Celgene - Quick Facts (RTTNews)
17.12.13	Amgen Reports Positive Top-Line Results From Phase3 MENDEL-2 Trial Of Evolocumab (RTTNews)
11.12.13	Agios Pharma And Celgene Extend Cancer Metabolism Collaboration - Quick Facts (RTTNews)
08.12.13	First Analysis Of Extended Dosing With Celgene's CC-486 Presented At ASH (RTTNews)
03.12.13	OncoMed, Celgene To Jointly Advance Multiple Anti-Cancer Stem Cell Therapeutics (RTTNews)
25.11.13	AMGN, GSK Get FDA Nod, CLDX Walks The Talk, OREX Awaits Light, CELG On A High (RTTNews)
22.11.13	Celgene: ABRAXANE In Combination With Gemcitabine Gets Positive CHMP Opinion (RTTNews)
22.11.13	Celgene erhält positive CHMP-Stellungnahme für ABRAXANE® in Kombination mit Gemcitabin zur Behandlung von Patienten mit metastasiertem Pankreaskarzinom (Businesswire)
22.11.13	Celgene Receives Positive CHMP Opinion for ABRAXANE® in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer (Businesswire)
19.11.13	Celgene Invests $6.0 Mln In Alliqua - Quick Facts (RTTNews)
07.11.13	Celgene Reports Data From Phase III Study Of REVLIMID (RTTNews)
28.10.13	Celgene Int'l Sàrl Reports Results Of 3 Long-term PhaseIII Studies Of Apremilast (RTTNews)
24.10.13	Celgene Q3 Results Top Estimates; Boosts 2013 Outlook (RTTNews)
24.10.13	Celgene Q3 Profit Falls, Adj. EPS Tops Estimates; Lifts FY Adj. Profit View (RTTNews)
22.10.13	Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics (PR Newswire)
14.10.13	Trial Updates and Public Offering - Research Report on Gilead, Celgene, Ariad, Puma Biotechnology, and Dyax (PR Newswire)
09.10.13	Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. (PR Newswire)
04.10.13	Conference Calls, Philanthropic Activities, Clinical Trial Data, and Regulatory Approvals - Research Report on Celgene, UnitedHealth, Biogen Idec, WellPoint, and Medtronic (PR Newswire)
03.10.13	Oral verabreichtes Apremilast bewirkte signifikante Verbesserung von Nagel- und Kopfhautpsoriasis sowie gesundheitsbezogener Lebensqualität in Phase-III-Studie ESTEEM 1 (Businesswire)
03.10.13	Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study (Businesswire)
02.10.13	Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus (PR Newswire)
25.09.13	Data Presentations, FDA Approvals, Board Appointments, Updated Clinical Results and New Contracts - Research Report on Vertex, Celgene, NPS Pharmaceuticals, Cyclacel and BioCryst (PR Newswire)
24.09.13	Critical Alerts For Walter Energy, Celgene, GlaxoSmithKline, UnitedHealth Group, and Safeway Released By InvestorsObserver (PR Newswire)
12.09.13	FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations, and Supply Agreements - Research Report on Celgene, Amgen, Biogen Idec, Vertex, and Illumina (PR Newswire)
11.09.13	Nuvilex Eyes FDA Fast-Track After Abraxane Approved For Pancreatic Cancer (RTTNews)
06.09.13	Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. (PR Newswire)
06.09.13	FDA OKs ABRAXANE Combined With Gemcitabine For Metastatic Pancreatic Cancer (RTTNews)
05.09.13	Celgene Provides Phase III Results On Pomalidomide Plus Low-dose Dexamethasone (RTTNews)
03.09.13	Pharmaceuticals Report Revolutionary Findings, Approved Treatments, Investor Conferences - Research Report on Celgene, Amgen, Biogen Idec, Regeneron, and Questcor (PR Newswire)
21.08.13	Healthy Outlook for Healthcare Supported by Trial Milestones, Approvals, Partnerships, and Commercialization - Research Report on Lilly, Celgene, Onyx, Amgen, and GSK (PR Newswire)
10.08.13	MorphoSys Lifts FY13 View As MOR202 Alliance With Celgene Turns Effective (RTTNews)
09.08.13	Celgene's Oral Anti-cancer Therapy Pomalidomide Gets EC Approval (RTTNews)
09.08.13	Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as Treatment for Patients with Relapsed/Refractory Multiple Myeloma – a Rare Form of Blood Cancer (Businesswire)
06.08.13	Solid Margins, Financial Strategies, and Earnings Reports Support Long-Term Growth in Biotech - Research Report on Gilead Sciences, Celgene, Onyx Pharmaceuticals, Questcor, and Amgen (PR Newswire)
02.08.13	Celgene Prices $1.5 Bln Of (RTTNews)
01.08.13	M&As, Strong Earnings, and Share Repurchase Programs Support Optimism for Healthcare - Research Report on Perrigo, Intuitive Surgical, Biogen Idec, Celgene, and Lilly (PR Newswire)
31.07.13	Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma (PR Newswire)
29.07.13	Array BioPharma, Celgene Announce Strategic R&D Collaboration - Quick Facts (RTTNews)
29.07.13	Acetylon Announces Strategic Collaboration, Option Agreement With Celgene (RTTNews)
25.07.13	Critical Alerts For ConocoPhillips, Celgene, Hershey, Lorillard, and Bunge Released By InvestorsObserver (PR Newswire)
25.07.13	Pre-market Movers For July 25 (GM, FB, BSX, BIIB, CELG, SI) (RTTNews)
25.07.13	Celgene Q2 Profit Rises - Quick Facts (RTTNews)
18.07.13	Pre-market Movers For July 18 (MS, VZ, NOK, CELG, CY, TZOO, SIFY, REDF) (RTTNews)
18.07.13	Celgene To Discontinue Treatment With Revlimid In Phase III ORIGIN Trial (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V

mehr

24.01.25		Verluste in New York: Dow Jones liegt am Mittag im Minus
24.01.25		Anleger in London halten sich zurück: FTSE 100 schwächelt zum Handelsende
24.01.25		Börse Europa: Euro STOXX 50 notiert schlussendlich um Nulllinie
24.01.25		Schwacher Handel: FTSE 100 verbucht Verluste
24.01.25		SLI aktuell: SLI in Grün
24.01.25		Börse Zürich: So steht der SMI aktuell
24.01.25		Schwacher Wochentag in London: FTSE 100 am Freitagmittag mit Abgaben
24.01.25		DAX 40-Titel Bayer-Aktie: So viel Verlust hätte ein Bayer-Investment von vor 3 Jahren eingefahren